**ONLINE APPENDIX**

**Table 1. Characteristics of those included and excluded (outside 1 year window) for DPT-1 analysis**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Included (n=282)** | **Excluded\* (n=87)** | **p-values** |
| **Age (yrs)** | **12.5±8.6** | **12.6±8.4** | **0.971** |
| **Body Mass Index (kg/m2)** | **20.7±8.2** | **19.8±4.7** | **0.342** |
| **Gender (% Female)** | **38.7** | **44.8** | **0.304** |
| **DPTRS** | **6.4±0.8** | **6.4±1.0** | **0.947** |
| **AUC Glucose (mg/dl)/120 min** | **118.5±18.3** | **120.0±21.03** | **0.881** |
| **AUC C-peptide (ng/ml)/120 min** | **4.0±1.6** | **4.1±1.7** | **0.530** |

**\*3 with missing values not included in table**

**Table 2. Characteristics of those included and excluded (outside 1 year window) for TrialNet analysis**

|  |  |  |  |
| --- | --- | --- | --- |
|  | | | |
|  | **Study Subjects**  **(n=340)** | **Excluded**  **(n=41)** | **p-values** |
| **Age (yrs)** | **9.4±5.6** | **11.4±8.4** | **0.146** |
| **Body Mass Index (kg/m2)** | **18.2±4.1** | **19.2±4.6** | **0.124** |
| **Gender (% Female)** | **37.4** | **41.5** | **0.608** |
| **DPTRS** | **6.4±0.8** | **6.3±0.9** | **0.643** |
| **AUC Glucose (mg/dl)/120 min** | **122.8±16.2** | **122.1±16.7** | **0.792** |
| **AUC C-peptide (ng/ml)/120 min** | **4.7±2.1** | **4.8±2.0** | **0.668** |
| **30-0 minute C-peptide (ng/ml)** | **3.3±1.9** | **3.6±2.1** | **0.280** |

**Table 3. AUC Ratio (mean±SD) after 1 year for DPTRS≥6.75**

|  |  |  |
| --- | --- | --- |
|  | **AUC Ratio [(ng/ml)/(mg/dl)]x100** | |
| **Oral Insulin** | **Placebo** |
| **DPT-1**  **Placebo: n=53 Oral Insulin n=37** | **2.86±1.06+** | **2.42±1.03** |
| **TrialNet Placebo: n=58 Oral Insulin: n=60** | **3.06±1.13+\*** | **2.57±0.96** |

**+p<0.05 (baseline adjusted) for comparison with placebo group +\*p=0.057 with age adjustment (p-values<0.05 with DPTRS adjustment)**

**Table 4. Characteristics of oral insulin and placebo groups among high risk DPT-1 participants**

|  |  |  |  |
| --- | --- | --- | --- |
|  | | | |
|  | **Oral Insulin**  **(n=37)** | **Placebo**  **(n=53)** | **p-values** |
| **Age (yrs)** | **9.8±5.8** | **7.9±3.8** | **0.089** |
| **Log Body Mass Index** | **3.0±0.2** | **3.0±0.4** | **0.643** |
| **Gender (% Female)** | **37.8** | **45.3** | **0.482** |
| **DPTRS** | **7.1±0.3** | **7.3±0.5** | **0.072** |
| **Index60** | **0.9±0.4** | **0.8±0.5** | **0.586** |
| **AUC Glucose (mg/dl)/120 min** | **130.7±14.2** | **132.7±13.8** | **0.495** |
| **AUC C-peptide (ng/ml)/120 min** | **3.3±1.1** | **3.4±1.2** | **0.655** |

**Table 5. Characteristics of oral insulin and placebo groups among high risk TrialNet participants**

|  |  |  |  |
| --- | --- | --- | --- |
|  | | | |
|  | **Oral Insulin**  **(n=60)** | **Placebo**  **(n=58)** | **p-values** |
| **Age (yrs)** | **7.3±3.7** | **6.3±2.8** | **0.110** |
| **Log Body Mass Index** | **2.8±0.2** | **2.8±0.2** | **0.836** |
| **Gender (% Female)** | **36.7** | **34.5** | **0.804** |
| **DPTRS** | **7.1±0.3** | **7.2±0.4** | **0.269** |
| **Index60** | **0.8±0.5** | **1.0±0.5** | **0.212** |
| **AUC Glucose (mg/dl)/120 min** | **124.2±11.5** | **122.0±13.3** | **0.327** |
| **AUC C-peptide (ng/ml)/120 min** | **3.8±1.5** | **3.5±1.2** | **0.130** |

**Diabetes Prevention Trial Type-1 Risk Score (DPTRS)**

The DPTRS was derived from the Diabetes Prevention Trial-Type 1 study and validated in the Trialnet Pathway to Prevention study. The calculation of the score (shown below) is based upon coefficients derived from proportional hazards regression**.**

0.813 × [Glucose Sum (mg/dl)/100] - 0.848 × [C-peptide Sum (ng/ml)/10] - 0.056 × [Age (years)]

+1.569 × [log-BMI (kg/m2)] +0.476 × [log-Fasting C-peptide (ng/ml)]

(Glucose and C-peptide Sums are from 30 + 60 + 90 +120 minute totals)

**Steering Committee:** Carla J. Greenbaum (Benaroya Research Institute), Mark A. Atkinson (University of Florida), David A. Baidal (University of Miami), Manuela Battaglia (San Raffaele University), Dorothy Becker (University of Pittsburgh), Penelope Bingley (University of Bristol), Emanuele Bosi (San Raffaele University), Jane Buckner (Benaroya Research Institute), Mark Clements (The Children’s Mercy Hospital), Peter G. Colman (Walter & Eliza Hall Institute of Medical Research), Linda DiMeglio (Indiana University), Carmella Evans-Molina (Indiana University), Stephen E. Gitelman (University of California, San Francisco), Robin Goland (Columbia University), Peter Gottlieb (Barbara Davis Center for Childhood Diabetes), Kevan Herold (Yale University), Mikael Knip (University of Helsinki), Jeffrey P. Krischer (University of South Florida), Ake Lernmark (Skane University Hospital), Wayne Moore (The Children’s Mercy Hospital), Antoinette Moran (University of Minnesota), Andrew Muir (Emory Children’s Center), Jerry Palmer (University of Washington), Mark Peakman (King’s College), Louis Philipson (University of Chicago), Philip Raskin (University of Texas Southwestern), Maria Redondo (Baylor College of Medicine), Henry Rodriguez (University of South Florida Diabetes and Endocrinology Center), William Russell (Vanderbilt Eskind Diabetes Clinic), Desmond A. Schatz (University of Florida), Jay M. Sosenko (University of Miami), Lisa Spain (National Institute of Diabetes and Digestive and Kidney Diseases [NIDDK]), John Wentworth (Walter & Eliza Hall Institute of Medical Research), Diane Wherrett (University of Toronto), Darrell M. Wilson (Stanford University), William Winter (University of Florida), Anette Ziegler (Technical University Munich).

**Past Members:** Mark Anderson (University of California, San Francisco), Peter Antinozzi (Wake Forest University), Richard Insel (Juvenile Diabetes Research Foundation [JDRF]), Thomas Kay (St. Vincent’s Institute of Medical Research), Jennifer B. Marks (University of Miami), Alberto Pugliese (University of Miami), Bart Roep (Leiden University Medical Center), Jay S. Skyler (University of Miami), Jorma Toppari (Hospital District of Southwest Finland).

**Executive Committee:** Carla J. Greenbaum (Benaroya Research Institute), Jeffrey P. Krischer (University of South Florida), Ellen Leschek (National Institute of Diabetes and Digestive and Kidney Diseases [NIDDK]), Lisa Spain (National Institute of Diabetes and Digestive and Kidney Diseases [NIDDK]).

**Past Members:** Katarzyna Bourcier (National Institute of Allergy and Infectious Diseases [NIAID]), Richard Insel (Juvenile Diabetes Research Foundation [JDRF]), John Ridge (National Institute of Allergy and Infectious Disease [NIAID]), Jay S. Skyler (University of Miami).

**Chair's Office:** Carla J. Greenbaum (Benaroya Research Institute), Lisa Rafkin (University of Miami), Jay M. Sosenko (University of Miami).

**Past Members:** Jay S. Skyler (University of Miami), Irene Santiago (University of Miami).

**TrialNet Coordinating Center (University of South Florida):** Jeffrey P. Krischer, Brian Bundy, Michael Abbondondolo, Timothy Adams, Ilma Asif, Jenna Bjellquist, Matthew Boonstra, Cristina Burroughs, Mario Cleves, David Cuthbertson, Meagan DeSalvatore, Christopher Eberhard, Steve Fiske, Julie Ford, Jennifer Garmeson, Susan Geyer, Brian Hays, Courtney Henderson, Martha Henry, Kathleen Heyman, Belinda Hsiao, Christina Karges, Beata-Gabriela Koziol, Lindsay Lane, Shu Liu, Jennifer Lloyd, Kristin Maddox, Jamie Malloy, Julie Martin, Cameron McNeill, Margaret Moore, Sarah Muller, Thuy Nguyen, Jodie Nunez, Ryan O’Donnell, Melissa Parker, MJ Pereyra, Amy Roberts, Kelly Sadler, Christine Sullivan, Roy Tamura, Elon Walker-Veras, Megan V. Warnock, Keith Wood, Rebecca Wood, Ping Xu, Vanessa Yanek, Kenneth Young.

**Past Members:** Darlene Amado, Amanda Kinderman, Ashley Leinbach, Jessica Miller, Nichole Reed, Tina Stavros.

**National Institute of Diabetes and Digestive and Kidney Diseases [NIDDK]:** Ellen Leschek, Lisa Spain.

**Data Safety and Monitoring Board:** Emily Blumberg (University of Pennsylvania), Sean Aas (Georgetown University), Gerald Beck (Cleveland Clinic Foundation), Rose Gubitosi-Klug (Case Western Reserve University), Lori Laffel (Joslin Diabetes Center), Robert Vigersky (Medtronic), Dennis Wallace (Research Triangle Institute).

**Past Members:** David Brillon (Cornell University), Robert Veatch (Georgetown University).

**Infectious Disease Safety Committee:** Brett Loechelt (Children's National Medical Center), Lindsey Baden (Brigham and Women's Hospital), Peter Gottlieb (Barbara Davis Center for Childhood Diabetes), Michael Green (University of Pittsburgh), Ellen Leschek (National Institute of Diabetes and Digestive and Kidney Diseases [NIDDK]), Adriana Weinberg (University of Colorado).

**Collaborative Mechanistic Studies Panel:** Peter A. Gottlieb (Barbara Davis Center for Childhood Diabetes), Mark Anderson (University of California, San Francisco), Mark A. Atkinson (University of Florida), Todd M. Brusko (University of Florida), Jane H. Buckner (Benaroya Research Institute), Carmella Evans-Molina (Indiana University), Kevan C. Herold (Yale University), Martin J. Hessner (Medical College of Wisconsin), Peter S. Linsley (Benaroya Research Institute), S. Alice Long (Benaroya Research Institute), Sarah Muller (University of Florida), David A. G. Skibinski (Benaroya Research Institute).

**Past Members:** Manuela Battaglia (San Raffaele University), Mark Peakman (King’s College).

**Laboratory Directors:** Santica Marcovina (University of Washington), Jerry P. Palmer (University of Washington), Jay Tischfield (Rutgers University), Adriana Weinberg (University of Colorado), William Winter (University of Florida), Liping Yu (Barbara Davis Center for Childhood Diabetes).

**TrialNet Clinical Network Hub (Benaroya Research Institute):** Annie Shultz, Emily Batts, Arielle Pagryzinski, Mary Ramey, Meghan Tobin.

**Past Members:** Kristin Fitzpatrick, Randy Guerra, Melita Romasco, Christopher Webb.